Eritrea vs Mozambique: Statin use vs. average non-HDL cholesterol levels
Eritrea
3
in 2018
Mozambique
3
in 2018
Eritrea rank
146th
Mozambique rank
146th
Statin use vs. average non-HDL cholesterol levels over time
- Eritrea
- Mozambique
How they compare
Eritrea currently reports 3 against 3 in Mozambique, a difference of 0.
The two have swapped places 8 times across 39 shared years of data; in 1980 it was Mozambique ahead.
Eritrea ranks 146th and Mozambique ranks 146th of 191 countries.
Across the 4 decades both report, Eritrea averaged higher in 3 and Mozambique in 1.
Head to head by decade
| Decade | Eritrea | Mozambique | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 2.49 | 2.47 | 0.02 | Eritrea |
| 1990s | 2.65 | 2.66 | 0.01 | Mozambique |
| 2000s | 2.82 | 2.76 | 0.06 | Eritrea |
| 2010s | 2.97 | 2.91 | 0.0556 | Eritrea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Eritrea or Mozambique?
- Eritrea, at 3 against 3 in Mozambique as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Eritrea and Mozambique?
- 0, with Eritrea ahead.
- How many years of comparable data are there for Eritrea and Mozambique?
- 39 years are reported by both, from 1980 to 2018.
- How do Eritrea and Mozambique rank globally for statin use vs. average non-hdl cholesterol levels?
- Eritrea ranks 146th and Mozambique ranks 146th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.